cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Magenta Therapeutics Inc
6 own
14 watching
Current Price
$0.82
$0.01
(0.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
49.66M
52-Week High
52-Week High
3.62
52-Week Low
52-Week Low
0.321
Average Volume
Average Volume
5.73M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization49.66M
icon52-Week High3.62
icon52-Week Low0.321
iconAverage Volume5.73M
iconDividend Yield--
iconP/E Ratio--
What does the Magenta Therapeutics Inc do?
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Magenta Therapeutics Inc make?
News & Events about Magenta Therapeutics Inc.
PR Newswire
5days ago
Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai? Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai? PR Newswire NEW YORK, Feb. 3, 2023 NEW YORK, Feb. 3, 2023...
Globe Newswire
1month ago
Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities Plan to Dose Additional Participants in Cohort 3 per Clinical Trial Protocol CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial ...
Globe Newswire
1month ago
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics(Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at ...
Globe Newswire
3 months ago
New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presentation of clinical ...
Globe Newswire
3 months ago
Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism Poster presentation of data from a MGTA-117 non-human primate study that has provided predictive modeling of biologic activity in the ongoing Phase 1/2 dose ...
Frequently Asked Questions
Frequently Asked Questions
What is Magenta Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Magenta Therapeutics Inc shares?
plus_minus_icon
How can I buy Magenta Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Magenta Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Magenta Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Magenta Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Magenta Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Magenta Therapeutics Inc?
plus_minus_icon
What percentage is Magenta Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Magenta Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.82
$0.01
(0.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.08
$-0.01 (-0.92 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.12
$0.02 (1.82 %)
Surface Oncology Inc
Surface Oncology Inc
$0.92
$-0.02 (-2.65 %)
I-Mab
I-Mab
$5.02
$-0.13 (-2.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.08
$-0.01 (-0.92 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.12
$0.02 (1.82 %)
Surface Oncology Inc
Surface Oncology Inc
$0.92
$-0.02 (-2.65 %)
I-Mab
I-Mab
$5.02
$-0.13 (-2.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00